Verneeda Spencer
Medical Oncology · Seattle, WANPI 1124054655
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,608 and has fallen 98.5% since, to $23 in 2023. That places this record below the midpoint for medical oncology clinicians in WA, where the typical reported total is $2,355.
Across 63 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$230
- Bristol Myers Squibb$207
- AstraZeneca$198
- Genentech USA, Inc.$128
- Rigel Pharmaceuticals, Inc.$108
- Clovis Oncology, Inc.$99
- plus $719 from 21 others
What the payments were for
- Food & beverage$1,53091%
- Education$1609%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 5 | $230 |
| Bristol Myers Squibb | 6 | $207 |
| AstraZeneca | 5 | $198 |
| Genentech USA, Inc. | 4 | $128 |
| Rigel Pharmaceuticals, Inc. | 1 | $108 |
| Clovis Oncology, Inc. | 6 | $99 |
| Amgen | 3 | $85 |
| Novartis | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Johnson & Johnson | 4 | $60 |
| Eisai Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Bayer | 2 | $42 |
| Pfizer | 2 | $39 |
| Tesaro, Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Spectrum Pharmaceuticals Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Sanofi | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| AbbVie | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,690 in reported general payments places this provider in the 45th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.